FDA Approved: NEORAL — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for NEORAL (cyclosporine) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection
• Psoriasis
• Rheumatoid Arthritis

Drugs mentioned

• NEORAL (CYCLOSPORINE)

Snippet

SUPPL AP for NEORAL (CYCLOSPORINE)